Frontlight ResearchEarly access
Taking people in United StatesNo phase
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- Brooklyn and New York, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- People taking part
- 510 people, planned
- Started
- 1 Jul 2021
- Planned end
- 30 Jul 2026
- Type of study
- Observational
- Treatments tested
- Cardiac MRI
- Echocardiogram
- 6-minute walk test
- Questionnaire
- Record updated
- 22 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Emergency room presentation and/or hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea/vomiting, myalgias, fever, syncope/presyncope
Who cannot take part
- Inability to provide informed consent (e.g. cognitive impairment)
- Unrelated condition (e.g. neoplasm) with life expectancy <12 months prohibiting follow-up
- Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate < 30 ml/min/1.73m2) will undergo non-contrast MRI but will not be excluded from this study
- Contraindication to CMR (i.e. non-compatible pacemaker/defibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) <30 ml/min/1.73m2)
- Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol
This trial is currently available in United States.
- New York-Presbyterian/Brooklyn Methodist HospitalBrooklyn, United StatesContact: Marline Attallah, MDTaking people
- New York Presbyterian QueensNew York, United StatesContact: Susan IngenitoTaking people
- Weill Cornell Medicine-New York Presbyterian HospitalNew York, United StatesContact: Elizabeth Manowitz, BSTaking people
About the trial
What the trial wants to find out
The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.
The group in the trial
- Diagnosed with COVID-19
Participants in the study cohort will have been diagnosed with COVID-19 by a PCR (polymerase chain reaction) positive test
Treatment: Cardiac MRI, Echocardiogram, 6-minute walk test, and Questionnaire
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors
- Record updated
- 22 January 2026